Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
About the study
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Is able to read, understand, and provide written, dated informed consent prior to Screening Visit.
- Is male or female, between 18 and 85 years of age at Screening Visit.
- Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
- Has experienced dyskinesia
- Has stable peak-effect dyskinesia
- Has more than one hour of "ON" time with troublesome dyskinesia
EXCLUSION CRITERIA
Exclusion Criteria:
- Has undergone surgery for the treatment of PD
- Has a current diagnosis of Substance Use
- Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses
- Has current seizure disorders requiring treatment with anticonvulsants.
Other criteria related to other medical conditions to be referred to the protocol.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Dyskinesias,Parkinson Disease
Age (in years)
18 - 85
Phase
Phase 2
Participants needed
188
Est. Completion Date
Jul 17, 2024
Treatment type
Interventional
Sponsor
Bukwang Pharmaceutical
ClinicalTrials.gov identifier
NCT04377945
Study number
BK-JM-201
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?